SBC Medical Group Holdings Incorporated (SBC)
Official siteINDUSTRIALS • CONSULTING SERVICES • NASDAQ
Market Cap: $755.92M
Last updated: Nov 17, 2026 at 11:06 AM ET
SBC Medical Group Holdings Incorporated (SBC) Earnings: Report Dates and Results
SBC Medical Group Holdings (SBC) is expected to report earnings on Mar 25, 2027. In the quarter ended Sep 30, 2026, SBC Medical Group Holdings reported EPS of $0.15, above the $0.11 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SBC has an expected report date of Mar 25, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% below the $0.14 reported for the quarter ended Dec 31, 2025.
SBC Earnings Call
The latest SBC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 9 quarters below that had an estimate, SBC beat 5 and missed 4. Revenue for the quarter ended Sep 30, 2026 was $58.58M, up 35.1% from $43.35M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.15 | $0.11 | $0.10 - $0.13 | +36.36% | Beat | +25.0% | 4 | 2 up, 2 down | Nov 13, 2026 | $58.58M |
| Jun 30, 2026 | $0.10 | $0.12 | $0.11 - $0.13 | -16.67% | Miss | +400.0% | 4 | 1 up, 1 down | Aug 13, 2026 | $49.19M |
| Mar 31, 2026 | $0.11 | $0.10 | $0.08 - $0.12 | +10.00% | Beat | -47.6% | 4 | 0 up, 0 down | May 14, 2026 | $43.06M |
| Dec 31, 2025 | $0.14 | $0.11 | $0.10 - $0.15 | +27.27% | Beat | +133.3% | 4 | 0 up, 0 down | Mar 27, 2026 | $39.57M |
| Sep 30, 2025 | $0.12 | $0.11 | $0.09 - $0.15 | +9.09% | Beat | +300.0% | 3 | 0 up, 0 down | Nov 14, 2025 | $43.35M |
| Jun 30, 2025 | $0.02 | $0.14 | $0.13 - $0.14 | -85.71% | Miss | -99.1% | 2 | 1 up, 0 down | Aug 13, 2025 | $43.36M |
| Mar 31, 2025 | $0.21 | $0.11 | N/A | +90.91% | Beat | N/A | N/A | N/A | May 15, 2025 | $47.33M |
| Dec 31, 2024 | $0.06 | $0.19 | $0.19 - $0.19 | -68.42% | Miss | N/A | 1 | 0 up, 0 down | Mar 28, 2025 | $44.42M |
| Sep 30, 2024 | $0.03 | $2.36 | N/A | -98.73% | Miss | N/A | N/A | N/A | Nov 13, 2024 | $53.08M |
| Jun 30, 2024 | $2.33 | N/A | N/A | N/A | N/A | +11156.0% | N/A | N/A | Aug 28, 2024 | $53.10M |
| Mar 31, 2024 | -$0.05 | N/A | N/A | N/A | N/A | -234.9% | N/A | N/A | Jun 17, 2024 | $54.81M |
| Dec 31, 2023 | -$0.04 | N/A | N/A | N/A | N/A | -209.2% | N/A | N/A | Dec 31, 2023 | $146.26M |
| Sep 30, 2023 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2023 | $47.28M |
| Jun 30, 2023 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2023 | N/A |
| Mar 31, 2023 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2023 | N/A |
| Dec 31, 2022 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 9, 2023 | N/A |
| Sep 30, 2022 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2022 | N/A |
| Jun 30, 2022 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Sep 9, 2022 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.49, down 79.3% from the year before. It was $0.04 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.49 | -79.3% |
| Dec 31, 2024 | $2.37 | N/A |
| Dec 31, 2023 | $0.00 | N/A |
| Dec 31, 2022 | $0.04 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,959 | 4 | |
| 2026Q2 | Jun 30, 2026 | 4,907 | 4 |
2026Q3 Earnings Call
Opening remarks
Hikaru Fukui Moderator Serving as your moderator. Today's presentation materials are posted on our IR website, and the transcript will be posted as soon as it is available. Please note that today's remarks include forward-looking statements. These are not guarantees of future performance, and actual results may differ due to various factors. For details, please refer to our SEC filings. We will also refer to certain non-GAAP measures. Reconciliation to GAAP is provided in today's disclosure materials. Let me walk you through today's program. First, we will show an AI-powered presentation of approximately 10 minutes. Please rest assured that the content has been reviewed in advance. Following the presentation, Yuya Yoshida will share a few remarks, after which we will move to the question-and-answer session. To ask questions, please click the Q&A icon at the bottom of your screen, type your message, and send it. Now, let us begin the presentation.
Yuya Yoshida CEO Thank you for taking the time to join our conference call today. I will now walk you through our results for the third quarter of fiscal 2026, an update on our business strategy, and our capital and IR. If I had to sum up this quarter in a single sentence, it is the quarter in which SBC's growth clearly re-accelerated. Revenue rose 35% year-on-year. Income from operations grew 66%, and our adjusted EBITDA margin reached 47%. Growth and profitability are improving in tandem, exactly the operating leverage we have been building toward, and a clear demonstration of the strength of our highly profitable MSO model. Let me begin with the clinic highlights, which demonstrate the underlying strength of our business. For the first nine months of the year, same-clinic revenue reached $836 million, up 7% year-on-year, continuing its steady growth. What is particularly encouraging is that our growth is being driven by both more customers and higher spend per visit, rising together. Over the trailing 12 months, we recorded 7.06 million customer visits, up 9% year-on-year, from 2.26 million unique customers, up 10%. At the same time, average spend per visit increased 4% to $290. Our clinic network also expanded by 36 locations year-on-year, reaching 293 locations. In short, our existing clinics are growing stronger while our network continues to expand, a powerful combination for sustainable growth. Next, our financial highlights. Third-quarter revenue was $59 million, up 35% year-on-year. Income from operations was $26 million, up 66%. Adjusted EBITDA was $28 million, also up 66%. And our adjusted EBITDA margin reached 47%, an improvement of 9 points year-on-year. Basic EPS was $0.15, up 25%. Profit grew far faster than revenue, and our operating margin expanded from 37% to 45% year-on-year. This is the operating leverage built into our MSO model.
Frequently Asked Questions About SBC
When is SBC Medical Group Holdings's next earnings date?
SBC Medical Group Holdings's next earnings report is expected for Mar 25, 2027.
Did SBC beat earnings estimates last quarter?
Yes. SBC Medical Group Holdings reported EPS of $0.15 for the quarter ended Sep 30, 2026, above the $0.11 estimate, a 36.36% surprise.
What EPS do analysts expect from SBC next quarter?
The consensus EPS estimate for SBC Medical Group Holdings for the quarter ending Dec 31, 2026 is $0.12 from 6 analysts, with estimates from $0.10 to $0.14.
How often does SBC beat earnings estimates?
SBC Medical Group Holdings beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.35%.
SBC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors